Home / Latest Reports / Rheumatoid Arthritis Drugs Market

Rheumatoid Arthritis Drugs Market By Drug Type and Distribution Channel - Global Industry Analysis And Forecast To 2027

Published On : February 2019 Pages : 155 Category: Pharmaceuticals Report Code : HC022567

Request Sample Inquiry Before Buying Request for Customization Check Discount

Rheumatoid Arthritis Drugs Market By Drug Type (Biologic Response Modifiers (Biologics), Nonsteroidal Anti-inflammatory Drugs (NSAIDS), Disease Modifying Anti-rheumatic Drugs (DMARDs), Corticosteroids and Other Drug Types) and Distribution Channel (Hospital Pharmacy, Online Pharmacy and Retail Pharmacy) - Global Industry Analysis And Forecast To 2027               

Industry Outlook

Rheumatoid Arthritis (RA) is a type of autoimmune disease that can cause damage throughout the body or cause pain in the joints. The damage that occurs to the joints is on both sides of the body i.e. if one joint is affected on one side of leg or arm the same will be affected on the other side. This is the reason that makes it easy for doctors to detect RA from other types of arthritis such as the osteoarthritis (OA). If the RA is detected early the effect of treatment is way to better, so it’s important to take note of the symptoms. The treatment of the condition is growing due to factors like; rising launches of more advanced procedures, increasing use of generic drugs across the globe, rising awareness amongst the people, increasing aged population, increasing use of combination drugs for treatment, etc. Therefore, the Rheumatoid Arthritis Drugs Market is anticipated to expand and has tremendous scope during the forecast period. The global Rheumatoid Arthritis Drugs Market anticipated to flourish in the future by growing at a significantly higher CAGR.

Market Segmentation

The global Rheumatoid Arthritis Drugs Market is based on segment, by Drug Type the market is segmented into Biologic Response Modifiers (Biologics), Nonsteroidal Anti-inflammatory Drugs (NSAIDS), Disease Modifying Anti-rheumatic Drugs (DMARDs), Corticosteroids and Other Drug Types, and by Distribution Channel the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy.

  • Rheumatoid Arthritis Drugs Market, By Drug Type
  • Biologic Response Modifiers (Biologics)
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
  • Disease Modifying Anti-rheumatic Drugs (DMARDs)
  • Corticosteroids
  • Other Drug Types
  • Rheumatoid Arthritis Drugs Market, By Distribution Channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Regional Insights

On a global front, the Rheumatoid Arthritis Drugs Market covers North America (United States, Canada and Mexico), Europe (Germany, UK, France, Russia, Italy, Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific), South America (Brazil, Argentina, Columbia, Rest of South America) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA). Asia Pacific region will dominate the global market over the projected period owing to rising expenditure ion the healthcare sector, rising number of cases of the condition in the region, etc.

Rheumatoid Arthritis Drugs Market, By Region

    • North America
  • U.S.
  • Canada
  • Mexico
    • Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
    • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Southeast Asia
  • Rest of Asia-Pacific
    • South America
  • Brazil
  • Argentina
  • Columbia
  • Rest of South America
    • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Nigeria
  • South Africa
  • Rest of MEA

Competitive Analysis

The leading players in the market are Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Janssen Biotech Inc., Merck & Co. Inc., Amgen Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi S.A. and Novartis AG. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and market share of the overall industry.

  • Eli Lilly and Company
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Janssen Biotech Inc.
  • Merck & Co. Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Sanofi S.A.
  • Novartis AG

Some of the key questions answered by the report are:          

  • What was the market size in 2017 and forecast from 2017 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

o   Rheumatoid Arthritis Drugs Market, By Drug Type, Estimates and Forecast, 2017-2027 ($Million)

o   Biologic Response Modifiers (Biologics)

o   Nonsteroidal Anti-inflammatory Drugs (NSAIDS)

o   Disease Modifying Anti-rheumatic Drugs (DMARDs)

o   Corticosteroids

o   Other Drug Types

o   Rheumatoid Arthritis Drugs Market, By Distribution Channel, Estimates and Forecast, 2017-2027 ($Million)

o   Hospital Pharmacy

o   Online Pharmacy

o   Retail Pharmacy

 

o   Rheumatoid Arthritis Drugs Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o   North America

§  North America Rheumatoid Arthritis Drugs Market, By Country

o   U.S. Rheumatoid Arthritis Drugs Market

o   Canada Rheumatoid Arthritis Drugs Market

o   Mexico Rheumatoid Arthritis Drugs Market

o   Europe

§  Europe Rheumatoid Arthritis Drugs Market, By Country

o   Germany Rheumatoid Arthritis Drugs Market

o   UK Rheumatoid Arthritis Drugs Market

o   France Rheumatoid Arthritis Drugs Market

o   Russia Rheumatoid Arthritis Drugs Market

o   Italy Rheumatoid Arthritis Drugs Market

o   Rest of Europe Rheumatoid Arthritis Drugs Market

o   Asia-Pacific

§  Asia-Pacific Rheumatoid Arthritis Drugs Market, By Country

o   China Rheumatoid Arthritis Drugs Market

o   Japan Rheumatoid Arthritis Drugs Market

o   South Korea  Rheumatoid Arthritis Drugs Market

o   India Rheumatoid Arthritis Drugs Market

o   Southeast Asia Rheumatoid Arthritis Drugs Market

o   Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market

o   South America

§  South America Rheumatoid Arthritis Drugs Market, By Country

o   Brazil Rheumatoid Arthritis Drugs Market

o   Argentina Rheumatoid Arthritis Drugs Market

o   Columbia Rheumatoid Arthritis Drugs Market

o   Rest of South America Rheumatoid Arthritis Drugs Market

o   Middle East and Africa

§  Middle East and Africa Rheumatoid Arthritis Drugs Market, By Country

o   Saudi Arabia Rheumatoid Arthritis Drugs Market

o   UAE Rheumatoid Arthritis Drugs Market

o   Egypt Rheumatoid Arthritis Drugs Market

o   Nigeria Rheumatoid Arthritis Drugs Market

o   South Africa Rheumatoid Arthritis Drugs Market

o   Rest of MEA Rheumatoid Arthritis Drugs Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

3.3.     SWOT Analysis

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Rheumatoid Arthritis Drugs  Market, By Drug Type

5.1.     Introduction

5.2.     Global Rheumatoid Arthritis Drugs  Revenue and Market Share by Drug Type (2017-2027)

5.2.1.  Global Rheumatoid Arthritis Drugs  Revenue and Revenue Share by Drug Type (2017-2027)

5.3.     Biologic Response Modifiers (Biologics)

5.3.1.  Global Biologic Response Modifiers (Biologics) Revenue and Growth Rate (2017-2027)

5.4.     Nonsteroidal Anti-inflammatory Drugs (NSAIDS)

5.4.1.  Global Nonsteroidal Anti-inflammatory Drugs (NSAIDS) Revenue and Growth Rate (2017-2027)

5.5.     Disease Modifying Anti-rheumatic Drugs (DMARDs)

5.5.1.  Global Disease Modifying Anti-rheumatic Drugs (DMARDs) Revenue and Growth Rate (2017-2027)

5.6.     Corticosteroids

5.6.1.  Global Corticosteroids Revenue and Growth Rate (2017-2027)

5.7.     Other Drug Types

5.7.1.  Global Other Drug Types Revenue and Growth Rate (2017-2027)

6.       Rheumatoid Arthritis Drugs  Market, By Distribution Channel

6.1.     Introduction

6.2.     Global Rheumatoid Arthritis Drugs  Revenue and Market Share by Distribution Channel (2017-2027)

6.2.1.  Global Rheumatoid Arthritis Drugs  Revenue and Revenue Share by Distribution Channel (2017-2027)

6.3.     Hospital Pharmacy

6.3.1.  Global Hospital Pharmacy Revenue and Growth Rate (2017-2027)

6.4.     Online Pharmacy

6.4.1.  Global Online Pharmacy Revenue and Growth Rate (2017-2027)

6.5.     Retail Pharmacy

6.5.1.  Global Retail Pharmacy Revenue and Growth Rate (2017-2027)

7.       Rheumatoid Arthritis Drugs  Market, By Region

7.1.     Introduction

7.2.     Global Rheumatoid Arthritis Drugs  Revenue and Market Share by Regions

7.2.1.  Global Rheumatoid Arthritis Drugs  Revenue by Regions (2017-2027)

7.3.     North America Rheumatoid Arthritis Drugs  by Countries

7.3.1.  North America Rheumatoid Arthritis Drugs  Revenue and Growth Rate (2017-2027)

7.3.2.  North America Rheumatoid Arthritis Drugs  Revenue (Million USD) by Countries (2017-2027)

7.3.3.  United States

7.3.3.1.  United States Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.4.  Canada

7.3.4.1.  Canada Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.3.5.  Mexico

7.3.5.1.  Mexico Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.     Europe Rheumatoid Arthritis Drugs  by Countries

7.4.1.  Europe Rheumatoid Arthritis Drugs  Revenue and Growth Rate (2017-2027)

7.4.2.  Europe Rheumatoid Arthritis Drugs  Revenue (Million USD) by Countries (2017-2027)

7.4.3.  Germany

7.4.3.1.  Germany Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.4.  France

7.4.4.1.  France Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.5.  UK

7.4.5.1.  UK Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.6.  Russia

7.4.6.1.  Russia Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.7.  Italy

7.4.7.1.  Italy Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.     Asia-Pacific Rheumatoid Arthritis Drugs  by Countries

7.5.1.  Asia-Pacific Rheumatoid Arthritis Drugs  Revenue and Growth Rate (2017-2027)

7.5.2.  Asia-Pacific Rheumatoid Arthritis Drugs  Revenue (Million USD) by Countries (2017-2027)

7.5.3.  China

7.5.3.1.  China Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.4.  Japan

7.5.4.1.  Japan Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.5.  Korea

7.5.5.1.  Korea Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.6.  India

7.5.6.1.  India Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.     South America Rheumatoid Arthritis Drugs  by Countries

7.6.1.  South America Rheumatoid Arthritis Drugs  Revenue and Growth Rate (2017-2027)

7.6.2.  South America Rheumatoid Arthritis Drugs  Revenue (Million USD) by Countries (2017-2027)

7.6.3.  Brazil

7.6.3.1.  Brazil Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.4.  Argentina

7.6.4.1.  Argentina Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.5.  Columbia

7.6.5.1.  Columbia Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.     Middle East and Africa Rheumatoid Arthritis Drugs  by Countries

7.7.1.  Middle East and Africa Rheumatoid Arthritis Drugs  Revenue and Growth Rate (2017-2027)

7.7.2.  Middle East and Africa Rheumatoid Arthritis Drugs  Revenue (Million USD) by Countries (2017-2027)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.5.  Egypt

7.7.5.1.  Egypt Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.7.  South Africa

7.7.7.1.  South Africa Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.8.  Turkey

7.7.8.1.  Turkey Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

8.       Company Profiles

8.1.     Eli Lilly and Company

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.   Revenue and Market Share

8.2.     AbbVie Inc.

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.   Revenue and Market Share

8.3.     Bristol-Myers Squibb Company

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.   Revenue and Market Share

8.4.     Janssen Biotech Inc.

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.   Revenue and Market Share

8.5.     Merck & Co. Inc.

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.   Revenue and Market Share

8.6.     Amgen Inc.

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.   Revenue and Market Share

8.7.     F. Hoffmann-La Roche Ltd.

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.   Revenue and Market Share

8.8.     Pfizer Inc.

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.   Revenue and Market Share

8.9.     Sanofi S.A.

8.9.1.  Business Overview

8.9.2.   Service Portfolio

8.9.3.  Strategic Developments

8.9.4.   Revenue and Market Share

8.10. Novartis AG

8.10.1.      Business Overview

8.10.2.       Service Portfolio

8.10.3.      Strategic Developments

8.10.4.       Revenue and Market Share

9.       Global Rheumatoid Arthritis Drugs  Market Competition, by Manufacturer

9.1.     Global Rheumatoid Arthritis Drugs  Revenue and Market Share by Manufacturer (2017-2017)

9.2.     Global Rheumatoid Arthritis Drugs  Price By Region (2017-2017)

9.3.     Top 5 Rheumatoid Arthritis Drugs  Manufacturer Market Share

9.4.     Market Competition Trend

10.    Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.1. Global Rheumatoid Arthritis Drugs  Revenue (Millions USD) and Growth Rate (2017-2027)

10.2. Rheumatoid Arthritis Drugs  Market Forecast by Regions (2017-2027)

10.2.1.      North America Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.1.1. United States Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.1.2. Canada Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.1.3. Mexico Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.      Europe Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.1. Germany Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.2. France Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.3. UK Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.4. Russia Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.5. Italy Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.2.6. Rest of Europe Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.      Asia-Pacific Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.1. China Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.2. Japan Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.3. Korea Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.4. India Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.5. Southeast Asia Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.3.6. Rest of Asia-Pacific Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.4.      South America Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.4.1. Brazil Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.4.2. Argentina Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.4.3. Columbia Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.4.4. Rest of South America Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.      Middle East and Africa Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.1. Saudi Arabia Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.2. United Arab Emirates Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.3. Egypt Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.4. Nigeria Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.5. South Africa Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.6. Turkey Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.2.5.7. Rest of Middle East and Africa Rheumatoid Arthritis Drugs  Market Forecast (2017-2027)

10.3. Rheumatoid Arthritis Drugs  Market Forecast by Drug Type (2017-2027)

10.3.1.      Rheumatoid Arthritis Drugs  Forecast by Drug Type (2017-2027)

10.3.2.      Rheumatoid Arthritis Drugs  Market Share Forecast by Drug Type (2017-2027)

10.4. Rheumatoid Arthritis Drugs  Market Forecast by Distribution Channel (2017-2027)

10.4.1.      Rheumatoid Arthritis Drugs  Forecast by Distribution Channel (2017-2027)

10.4.2.      Rheumatoid Arthritis Drugs  Market Share Forecast by Distribution Channel (2017-2027)

List of Tables

List of Tables and Figures:

Figure United States Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Rheumatoid Arthritis Drugs Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Rheumatoid Arthritis Drugs Revenue and Revenue Share by Drug Type (2017-2018)
Figure Global Biologic Response Modifiers (Biologics) Revenue and Growth Rate (2017-2018)
Figure Global Nonsteroidal Anti-inflammatory Drugs (NSAIDS) Revenue and Growth Rate (2017-2018)
Figure Global Disease Modifying Anti-rheumatic Drugs (DMARDs) Revenue and Growth Rate (2017-2018)
Figure Global Corticosteroids Revenue and Growth Rate (2017-2018)
Figure Global Other Drug Types Revenue and Growth Rate (2017-2018)
Table Global Rheumatoid Arthritis Drugs Revenue and Revenue Share by Distribution Channel (2017-2018)
Figure Global Hospital Pharmacy Revenue and Growth Rate (2017-2018)
Figure Global Online Pharmacy Revenue and Growth Rate (2017-2018)
Figure Global Retail Pharmacy Revenue and Growth Rate (2017-2018)
Table Global Rheumatoid Arthritis Drugs Revenue by Regions (2017-2018)
Figure North America Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure North America Rheumatoid Arthritis Drugs Revenue and Growth Rate (2017-2018)
Figure North America Rheumatoid Arthritis Drugs by Countries (2017-2018)
Figure North America Rheumatoid Arthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure United States Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure United States Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Canada Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Mexico Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Europe Rheumatoid Arthritis Drugs Revenue and Growth Rate (2017-2018)
Figure Europe Rheumatoid Arthritis Drugs by Countries (2017-2018)
Figure Europe Rheumatoid Arthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Germany Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Germany Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure France Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure UK Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Russia Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Italy Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Rest of Europe Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Asia-Pacific Rheumatoid Arthritis Drugs Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Rheumatoid Arthritis Drugs by Countries (2017-2018)
Figure Asia-Pacific Rheumatoid Arthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure China Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure China Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Japan Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Korea Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure India Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Southeast Asia Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure South America Rheumatoid Arthritis Drugs Revenue and Growth Rate (2017-2018)
Figure South America Rheumatoid Arthritis Drugs by Countries (2017-2018)
Figure South America Rheumatoid Arthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Brazil Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Argentina Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Columbia Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Rest of South America Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Middle East and Africa Rheumatoid Arthritis Drugs Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Rheumatoid Arthritis Drugs by Countries (2017-2018)
Figure Middle East and Africa Rheumatoid Arthritis Drugs Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Saudi Arabia Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure United Arab Emirates Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Egypt Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Nigeria Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure South Africa Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Turkey Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Rheumatoid Arthritis Drugs Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2017-2018)
Table Eli Lilly and Company Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table AbbVie Inc. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Bristol-Myers Squibb Company Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Janssen Biotech Inc. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Merck & Co. Inc. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Amgen Inc. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table F. Hoffmann-La Roche Ltd. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Pfizer Inc. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Sanofi S.A. Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Table Novartis AG Rheumatoid Arthritis Drugs Price, Revenue, Gross Margin and Market Share (2017-2017)
Figure Global Rheumatoid Arthritis Drugs Market Share by Manufacturer
Figure Global Rheumatoid Arthritis Drugs Revenue and Market Share by Manufacturer
Table Global Rheumatoid Arthritis Drugs Price by Region (2017-2017)
Figure Top 5 Rheumatoid Arthritis Drugs Manufacturer (Revenue) Market Share
Figure Market Competition Trend
Figure Global Rheumatoid Arthritis Drugs Revenue (Millions USD) and Growth Rate (2018-2025)
Table Rheumatoid Arthritis Drugs Market Forecast by Regions (2018-2025)
Figure North America Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure United States Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Canada Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Mexico Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Europe Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Germany Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure France Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure UK Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Russia Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Italy Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Rest of Europe Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure China Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Japan Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Korea Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure India Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Southeast Asia Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure South America Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Brazil Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Argentina Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Columbia Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Rest of South America Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Middle East and Africa Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure United Arab Emirates Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Egypt Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Nigeria Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure South Africa Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Turkey Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Rheumatoid Arthritis Drugs Market Forecast (2018-2025)
Figure Global Rheumatoid Arthritis Drugs Forecast by Drug Type (2018-2025)
Figure Global Rheumatoid Arthritis Drugs Market Share Forecast by Drug Type (2018-2025)
Figure Global Rheumatoid Arthritis Drugs Forecast by Drug Type (2018-2025)
Figure Global Rheumatoid Arthritis Drugs Forecast by Distribution Channel (2018-2025)
Figure Global Rheumatoid Arthritis Drugs Market Share Forecast by Distribution Channel (2018-2025)
Figure Global Rheumatoid Arthritis Drugs Forecast by Distribution Channel (2018-2025)

Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources
  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources
  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)
  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*